CD274 and non-small cell lung carcinoma: For this reason, and in a context in which the efficiency of the health care system has to be considered, the aim of this economic evaluation was to assess the cost-effectiveness of atezolizumab versus pembrolizumab, for first-line treatment of advanced NSCLC patients expressing high levels of PD-L1 (≥ 50%) in Spain, based on the results of the two cut-offs of the IMpower110-study.